LPCN

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America ("SMSNA"). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation ("DV") study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting. The presentations will take place virtually on November 9, 2020 from 7:00 p.m. – 9:00 p.m. EST during Session 2 (Androgens and Ejaculation/Orgasm Disorders).

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN 1144, an oral product of bioidentical testosterone being evaluated for the treatment of non-cirrhotic, NASH at the H.C. Wainwright 4th Annual NASH Investor

Lipocine (LPCN) -1.2% announced that the last patient has been enrolled in its LiFT Phase 2 clinical study.LPCN 1144, an oral prodrug of endogenous testosterone has shown meaningful reductions of liver fat

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the last patient has been enrolled in its LiFT ("Liver Fat intervention with oral Testosterone") Phase 2 clinical study, a paired-biopsy study investigating

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conference. The conference will take place virtually September 14 – 16, 2020

Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%.

Shiloh Industries (SHLO) -50% after entering into stock and asset purchase agreement with Grouper Holdings.Lipocine (LPCN) -18% on extended timeline for FDA review of Tlando application.PEDEVCO (PED) -13%.BigCommerce Holdings (BIGC) -11% on sell-side caution.NIO Limited (NIO) -8% after pricing

Fortress Biotech reports positive data from CUTX-101.Lipocine suffers setback on Tlando front.Enanta presents positive data for NASH and HBV.